Lineage Cell Therapeutics, Inc.
LCTX
$0.9853
-$0.0347-3.40%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.49% | 13.39% | 12.81% | -9.82% | -0.42% |
| Total Depreciation and Amortization | -14.08% | -11.99% | -8.26% | -5.52% | -3.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.09% | 21.17% | -6.77% | 52.01% | -4.67% |
| Change in Net Operating Assets | -50.18% | 18.86% | 43.89% | 74.23% | 63.43% |
| Cash from Operations | 3.95% | 19.16% | 26.21% | 29.65% | 27.99% |
| Capital Expenditure | -19.08% | 16.17% | 48.68% | 55.46% | 5.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.18% | -103.70% | -84.18% | 131.27% | 204.57% |
| Cash from Investing | -101.18% | -104.97% | -84.82% | 126.53% | 200.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.85% | 0.00% | -6.00% | -13.04% | -45.95% |
| Issuance of Common Stock | 31.44% | 436.17% | 106.96% | 145.08% | 6,374.69% |
| Repurchase of Common Stock | 93.24% | 90.25% | -500.00% | -500.00% | -382.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 194.29% | -74.14% | -100.00% |
| Cash from Financing | 31.49% | 458.26% | 115.16% | 122.19% | 1,725.27% |
| Foreign Exchange rate Adjustments | 55.45% | 62.00% | 126.56% | 76.11% | 76.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.98% | -56.93% | -155.11% | 88.41% | 144.90% |